Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 195, Issue 6, 2017, Pages 814-823

  Olivier, Kenneth N ^a   Griffith, David E ^b   Eagle, Gina ^c   McGinnis, John P ^c   Micioni, Liza ^c   Liu, Keith ^c   Daley, Charles L ^d   Winthrop, Kevin L ^e   Ruoss, Stephen ^f   Addrizzo Harris, Doreen J ^g   Flume, Patrick A ^h   Dorgan, Daniel ⁱ   Salathe, Matthias ^j   Brown Elliott, Barbara A ^b   Gupta, Renu ^c,k   Wallace, Richard J ^b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT TYLER   (United States)

^c Insmed   (United States)

^d DEPARTMENT OF MEDICINE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^k Global Biopharma   (United States)

more..

Author keywords

Culture conversion; Efficacy; Nontuberculous mycobacteria; Safety

Indexed keywords

AMIKACIN; LIPOSOME; MACROLIDE; PLACEBO; ANTIINFECTIVE AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC PNEUMONITIS; ANTIBIOTIC RESISTANCE; ARTICLE; ATYPICAL MYCOBACTERIOSIS; BACTERIAL GROWTH; BLOOD SAMPLING; BRONCHIECTASIS; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; LUNG DISEASE; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; NEPHROLITHIASIS; OPEN STUDY; OROPHARYNX PAIN; PHASE 2 CLINICAL TRIAL; PNEUMONIA; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; TINNITUS; WHEEZING; ATYPICAL MYCOBACTERIUM; CLINICAL TRIAL; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AMIKACIN; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NONTUBERCULOUS MYCOBACTERIA; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 85015872577     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201604-0700OC     Document Type: Article

References (39)

1. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: An emerging public health disease. Am J Respir Crit Care Med 2010;182:977-982.
2. O'Connell ML, Birkenkamp KE, Kleiner DE, Folio LR, Holland SM, Olivier KN. Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease. Chest 2012; 141:1203-1209.
3. van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands. Thorax 2009;64:502-506.
4. Mirsaeidi M, Machado RF, Garcia JG, Schraufnagel DE. Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: A population-based comparative study. PLoS One 2014;9:e91879.
5. Thomson RM, Yew WW. When and how to treat pulmonary nontuberculous mycobacterial diseases. Respirology 2009;14:12-26.
6. Mehta M, Marras TK. Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med 2011;105:1718-1725.
7. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881-886.
8. Marras TK, Mendelson D, Marchand-Austin A, May K, Jamieson FB. Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis 2013;19:1889-1891.
9. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: Diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
10. Published erratum appears in Am J Respir Crit Care Med 2007;175:744-745.
11. Griffith DE, Aksamit TR. Therapy of refractory nontuberculous mycobacterial lung disease. Curr Opin Infect Dis 2012;25: 218-227.
12. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: Daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538-1544.
13. Rose SJ, Neville ME, Gupta R, Bermudez LE. Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection. PLoS One 2014;9:e108703.
14. Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61:859-868.
15. Okusanya OO, Bhavnani SM, Hammel J, Minic P, Dupont LJ, Forrest A, Mulder GJ, Mackinson C, Ambrose PG, Gupta R. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother 2009;53:3847-3854.
16. Contreras AM, Gamba G, Cortés J, Santiago Y, Nares F, Jimenez-Sanchez G, Bobadilla J, López G, Valadez A, Espinosa A, et al. Serial trough and peak amikacin levels in plasma as predictors of nephrotoxicity. Antimicrob Agents Chemother 1989;33:973-976.
17. Daglian D, Lau S, Eagle G, McGinnis J, Micioni L, Addrizzo-Harris D. Case report of a patient with treatment-refractory nontuberculous mycobacteria (NTM) lung infection treated with once daily (QD) liposomal amikacin for inhalation (LAI) [abstract]. Chest 2015;148(4 Suppl):162A.
18. Olivier KN, Griffith DE, Winthrop KL, Brown-Elliott BA, Eagle G, McGinnis J, Wallace RJ. 12-Month follow-up data from a phase 2 trial of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung infection [abstract]. Am J Respir Crit Care Med 2016;193:A3722.
19. Olivier KN, Maas-Moreno R, Whatley M, Cheng K, Lee J, Fiorentino C, Shaffer R, Macdonald S, Gupta R, Corcoran TE, et al. Airway deposition and retention of liposomal amikacin for inhalation in patients with pulmonary nontuberculous mycobacterial disease [abstract]. Am J Respir Crit Care Med 2016;193:A3732.
20. Rubino CM, Olivier KN, Griffith DE, Eagle G, McGinnis JP II, Micioni L, Winthrop KL. Pharmacokinetic (PK) evaluation of liposomal amikacin for inhalation (LAI) in patients with treatment-refractory nontuberculous mycobacteria (NTM) lung infection. Presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy/28th International Congress of Chemotherapy Meeting (ICAAC/ICC 2015). September 17-21, 2015, San Diego, CA, Poster A-012.
21. Olivier KN, Eagle G, McGinnis JP II, Micioni L, Brown-Elliott BA, Wallace RJ Jr. Amikacin (AMK) minimum inhibitory concentrations (MICs) and mutational resistance in patients with treatmentrefractory nontuberculous mycobacteria (NTM) lung disease (LD) treated with liposomal amikacin for inhalation (LAI) [abstract]. Eur Respir J 2015;46(Suppl 59):PA371.
22. Winthrop KL, Eagle G, McGinnis JP, Micioni L, Daley CL, Ruoss SJ, Addrizzo-Harris DJ, Flume PA, Dorgan DJ, Salathe M, et al. Subgroup analyses of baseline demographics and efficacy in patients with refractory nontuberculous mycobacteria (NTM) lung infection treated with liposomal amikacin for inhalation (LAI) [abstract]. Am J Respir Crit Care Med 2015;191:A6294.
23. Biller JA, Eagle G, McGinnis JP, Micioni L, Daley CL, Winthrop KL, Ruoss SJ, Addrizzo-Harris DJ, Flume PA, Dorgan DJ, et al. Efficacy of liposomal amikacin for inhalation (LAI) in achieving nontuberculous mycobacteria (NTM) culture negativity in patients whose lung infection is refractory to guideline-based therapy [abstract]. Am J Respir Crit Care Med 2015;191:A6295.
24. Ruoss SJ, Eagle G, McGinnis JP, Micioni L, Daley CL, Winthrop KL, Addrizzo-Harris DJ, Flume PA, Dorgan DJ, Salathe M, et al. Analysis of functional exercise capacity (via the six-minute walk test [6MWT]) and culture negativity in patients with nontuberculous mycobacteria (NTM) lung infection refractory to guideline-based therapy treated with liposomal amikacin for inhalation (LAI) [abstract]. Am J Respir Crit Care Med 2015;191:A6296.
25. Olivier KN, Eagle G, McGinnis JP, Micioni L, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, et al. Randomized, double-blind (DB), placebo-controlled study and open-label (OL) extension of liposomal amikacin for inhalation (LAI) in patients with refractory nontuberculous mycobacterial (NTM) lung disease (LD) [abstract WS02.3]. J Cyst Fibros 2015;14(Suppl 1):S3.
26. Olivier KN, Eagle G, McGinnis JP II, Micioni L, Daley CL, Winthrop KL, Ruoss S, Addrizzo-Harris DJ, Flume P, Dorgan D, et al. Randomized, double-blind, placebo-controlled, open-label study of liposomal amikacin for inhalation (LAI) in patients with recalcitrant nontuberculous mycobacterial lung disease (NTM-LD). Presented at the 28th Annual North American Cystic Fibrosis Conference (NACFC). October 9-11, 2014, Atlanta, GA.
27. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-1341.
28. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: The first 50 patients. Am J Respir Crit Care Med 1996;153:1766-1772.
29. Devallois A, Goh KS, Rastogi N. Rapid identification of mycobacteria to species level by PCR-restriction fragment length polymorphism analysis of the hsp65 gene and proposition of an algorithm to differentiate 34 mycobacterial species. J Clin Microbiol 1997;35:2969-2973.
30. Hall L, Doerr KA, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. J Clin Microbiol 2003;41:1447-1453.
31. Iakhiaeva E, Howard ST, Brown Elliott BA, McNulty S, Newman KL, Falkinham JO III, Williams M, Kwait R, Lande L, Vasireddy R, et al. Variable-number tandem-repeat analysis of respiratory and household water biofilm isolates of "Mycobacterium avium subsp. hominissuis" with establishment of a PCR database. J Clin Microbiol 2016;54:891-901.
32. Iakhiaeva E, McNulty S, Brown Elliott BA, Falkinham JO III, Williams MD, Vasireddy R, Wilson RW, Turenne C, Wallace RJ Jr. Mycobacterial interspersed repetitive-unit-variable-number tandemrepeat (MIRU-VNTR) genotyping of Mycobacterium intracellulare for strain comparison with establishment of a PCR-based database. J Clin Microbiol 2013;51:409-416.
33. Brown-Elliott BA, Iakhiaeva E, Griffith DE,Woods GL, Stout JE,Wolfe CR, Turenne CY, Wallace RJ Jr. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 2013;51:3389-3394.
34. Published erratum appears in J Clin Microbiol. 2014;52:1311.
35. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minutewalk test. Am J Respir Crit Care Med 2002;166:111-117.
36. Seshadri P, Climaco AB. Amikacin level [updated 2014 Feb 7; accessed 2016 Aug 15]. Available from: Http://emedicine.medscape.com/ article/2089686-overview
37. Griffith DE, Adjemian J, Brown-Elliott BA, Philley JV, Prevots DR, Gaston C, Olivier KN, Wallace RJ Jr. Semiquantitative culture analysis during therapy for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2015;192:754-760.
38. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, et al.; Arikace Study Group. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68:818-825.
39. Olivier KN, Shaw PA, Glaser TS, Bhattacharyya D, Fleshner M, Brewer CC, Zalewski CK, Folio LR, Siegelman JR, Shallom S, et al. Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014;11:30-35.